MedPath

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD

Phase 3
Completed
Conditions
Pompe Disease (Late-onset)
Interventions
Registration Number
NCT04138277
Lead Sponsor
Amicus Therapeutics
Brief Summary

This is a multicenter, international open-label extension study of ATB200/AT2221 in adult subjects with late-onset Pompe disease (LOPD) who completed Study ATB200-03.

Detailed Description

This is an open label extension study for subjects who completed the ATB200-03 study. The subjects will stay in this study until regulatory approval or marketing authorization and/or commercialization in the participating subject's country.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
119
Inclusion Criteria
  1. Subject must have completed Study ATB200-03.

Exclusion Criteria

  1. Subject plans to receive gene therapy or participate in another interventional study for Pompe disease.
  2. Subject, if female, is pregnant or breastfeeding.
  3. Subject, whether male or female, is planning to conceive a child during the study.
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
ATB200/AT2221AT2221Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
ATB200/AT2221ATB200Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
Primary Outcome Measures
NameTimeMethod
Proportion of participants with Treatment Emergent Adverse Events (TEAE)baseline, up to approximately 4 years
Secondary Outcome Measures
NameTimeMethod
6-Minute Walk Testbaseline, up to approximately 4 years

Change in 6MWD from baseline to assess the efficacy of ATB200/AT2221 co-administration

Pulmonary Function - Forced vital capacity (FVC)baseline, up to approximately 4 years

Change from baseline in FVC (sitting) to assess the efficacy of ATB200/AT2221 co-administration

Change from baseline in muscle strength measured by Quantitative Muscle Strength testingbaseline, up to approximately 4 years
Change from baseline in muscle strength measured by Manual Muscle Strength testingbaseline, up to approximately 4 years
The Rasch-built Pompe-specific activity (R-PAct) questionnairesbaseline, up to approximately 4 years

Change in R-Pact from baseline to assess the efficacy of ATB200/AT2221 co-administration

EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) questionnairesbaseline, up to approximately 4 years

Change from baseline in scores of EQ-5D-5L questionnaire to assess the efficacy of ATB200/AT2221 co-administration.

Change from baseline in scores of PROMIS - physical function questionnairebaseline, up to approximately 4 years
Change from baseline in scores of PROMIS - fatigue questionnairebaseline, up to approximately 4 years
Change from baseline in scores of PROMIS - dyspnea questionnairebaseline, up to approximately 4 years
Change from baseline in scores of PROMIS - upper extremity questionnairebaseline, up to approximately 4 years
Motor Function - Gait, Stairs, Gower, Chair (GSGC) testbaseline, up to approximately 4 years

Change from baseline in GSGC score to assess the efficacy of ATB200/AT2221 co-administration.

Physician's Global Impression of Changebaseline, up to approximately 4 years

Change in the Physician's Global Impression of Change (PGIC) evaluation to assess the efficacy of ATB200/AT2221 co-administration.

Subject's Global Impression of Changebaseline, up to approximately 4 years

Change from baseline in scores of Subject's Global Impression of Change (SGIC) questionnaire to assess the efficacy of ATB200/AT2221 co-administration.

Change from baseline Biomarker -CKbaseline, up to approximately 4 years
Change from baseline Biomarker -uHex4baseline, up to approximately 4 years
Immunogenicity: Incidence of neutralizingbaseline, up to approximately 4 years
Immunogenicity: anti-drug antibodiesbaseline, up to approximately 4 years

Trial Locations

Locations (60)

Semmelweis University

🇭🇺

Budapest, Hungary

University of Pécs

🇭🇺

Pécs, Hungary

University of Szeged

🇭🇺

Szeged, Hungary

UOC di Neurologia e Malattie Neuromuscolari

🇮🇹

Messina, Italy

Universitaria Federico II

🇮🇹

Napoli, Italy

Fukuoka University Hospital

🇯🇵

Fukuoka, Japan

Kagoshima University Hospital

🇯🇵

Kagashima, Japan

Izumi City General Hospital

🇯🇵

Osaka, Japan

Hokkaido University Hospital

🇯🇵

Sapporo, Japan

The Jikei University Hospital

🇯🇵

Tokyo, Japan

Pusan National University

🇰🇷

Yangsan, Gyeongsangnam-do, Korea, Republic of

Erasmus MC

🇳🇱

Rotterdam, Netherlands

University of Auckland

🇳🇿

Auckland, New Zealand

Centrum Medyczne Medyk

🇵🇱

Rzeszów, Podkarpackie, Poland

Alberta Children's Hospital, Heritage Medical Research Clinic

🇨🇦

Calgary, Alberta, Canada

University of Arkansas for Medical Sciences

🇺🇸

Little Rock, Arkansas, United States

University of California, Irvine

🇺🇸

Irvine, California, United States

University of Florida Clinical Research Center

🇺🇸

Gainesville, Florida, United States

Emory Clinic

🇺🇸

Atlanta, Georgia, United States

IU Health Neuroscience Center

🇺🇸

Indianapolis, Indiana, United States

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

Billings Clinic

🇺🇸

Billings, Montana, United States

Hackensack University Medical Center

🇺🇸

Hackensack, New Jersey, United States

Northwell Health

🇺🇸

Great Neck, New York, United States

NYU School of Medicine

🇺🇸

New York, New York, United States

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

University of Cincinnati Gardner Neuroscience Institute

🇺🇸

Cincinnati, Ohio, United States

Cincinnati Children's Hospital

🇺🇸

Cincinnati, Ohio, United States

The Ohio State University Wexner Medical Center

🇺🇸

Columbus, Ohio, United States

University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

UPMC Montefiore Clinical and Translational Research Center

🇺🇸

Pittsburgh, Pennsylvania, United States

University of Utah

🇺🇸

Salt Lake City, Utah, United States

Lysosomal and Rare Disorders Research and Treatment Center, Inc.

🇺🇸

Fairfax, Virginia, United States

Hospital Universitario Austral

🇦🇷

Buenos Aires, Argentina

Westmead Hospital

🇦🇺

Westmead, New South Wales, Australia

Royal Brisbane & Women's Hospital

🇦🇺

Brisbane, Queensland, Australia

Royal Adelaide Hospital

🇦🇺

Adelaide, South Australia, Australia

Monash Medical Centre

🇦🇺

Clayton, Victoria, Australia

Medizinische Universität Innsbruck

🇦🇹

Innsbruck, Austria

UZ Leuven

🇧🇪

Leuven, Belgium

University Clinical Centre of the Republic of Srpska

🇧🇦

Banja Luka, The Republic Of Srpska, Bosnia and Herzegovina

McMaster University Medical Centre

🇨🇦

Hamilton, Ontario, Canada

Aarhus Universitetshospital

🇩🇰

Aarhus, Denmark

Hôpital Pierre Wertheimer

🇫🇷

Bron, France

Hôpital Raymond Poincaré

🇫🇷

Garches, France

Hôpital Salengro

🇫🇷

Lille, France

Hôpital de la Timone

🇫🇷

Marseille, France

Hôpital Pasteur 2

🇫🇷

Nice, France

Universitätsklinikum Bonn

🇩🇪

Bonn, Germany

Friedrich-Baur Institut

🇩🇪

München, Germany

Universitätsklinikum Münster

🇩🇪

Münster, Germany

Eginition Hospital

🇬🇷

Athens, Greece

University Medical Centre Ljubljana

🇸🇮

Ljubljana, Slovenia

Hospital de la Santa Creu I Sant Pau

🇪🇸

Barcelona, Spain

Sahlgrenska University Hospital

🇸🇪

Gothenburg, Sweden

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

Queen Elizabeth Hospital Birmingham

🇬🇧

Birmingham, United Kingdom

Cambridge University Hospitals NHS Foundation Trust

🇬🇧

Cambridge, United Kingdom

Royal Free Hospital NHS Foundation Trust

🇬🇧

London, United Kingdom

Salford Royal NHS Foundation Trust

🇬🇧

Salford, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath